CALCULATE YOUR SIP RETURNS

Orchid Pharma’s Alathur API Facility Passes USFDA Inspection

Written by: Team Angel OneUpdated on: Feb 20, 2025, 3:09 PM IST
Orchid Pharma Ltd.'s Alathur API facility has successfully cleared a surprise USFDA inspection with only minor observations.
Orchid Pharma’s Alathur API Facility Passes USFDA Inspection
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Orchid Pharma Ltd. has once again demonstrated its commitment to regulatory excellence by successfully completing a surprise inspection by the USFDA. This milestone not only cements its leadership in sterile cephalosporin production but also strengthens its global credibility.

Successful USFDA Inspection with No Major Issues

Orchid Pharma Ltd. has announced the successful completion of a surprise inspection by the U.S. Food and Drug Administration (USFDA) at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu.

The inspection, conducted between 10 and 18 February 2025, resulted in seven minor observations, none of which were related to data integrity concerns.

This development ensures that Orchid Pharma maintains its exclusive position as India’s only USFDA-approved manufacturing site for sterile cephalosporins. The facility plays a crucial role in the production of life-saving antibiotics, reinforcing the company’s global standing in the pharmaceutical industry.

Continued Global Compliance and Certification

Beyond the USFDA approval, the Alathur API facility has also secured the renewal of its European Union Good Manufacturing Practice (EU GMP) certification. This further validates Orchid Pharma’s commitment to stringent European regulatory standards, enabling the company to continue serving key international markets.

Commenting on the achievement, Manish Dhanuka, Managing Director of Orchid Pharma, stated, “The successful completion of the USFDA inspection underscores our unwavering commitment to quality, compliance, and global regulatory standards. Our teams have consistently worked towards upholding the highest manufacturing practices, ensuring the continued supply of world-class antibiotics.”

Orchid Pharma Share Performance

As of February 20, 2025, at 12:43 PM, the shares of Orchid Pharma are locked in an upper circuit at ₹874.55 per share, reflecting a surge of 5% from the previous day’s closing price.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Feb 20, 2025, 3:09 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 3 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 3 Cr+ happy customers